STREPTOCOCCUS SUIS POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION
The present invention relates to an immunogenic composition comprising polysaccharide-protein conjugates wherein each conjugate contains a capsular polysaccharide prepared from Streptococcus suis serotypes 1, 2, 7 and/or 9 or any other serotype conjugated to a carrier protein. The immunogenic composition is useful for the protection of disease in an animal subject.
1 . An immunogenic composition, comprising: a capsular polysaccharide-protein conjugate, together with a physiologically acceptable vehicle, wherein said conjugate comprises a capsular polysaccharide from Streptococcus suis conjugated to a carrier protein, wherein in said capsular polysaccharides are prepared from Streptococcus suis serotypes 1, 2, 7 or 9, or any other serotype or combinations thereof.
2 . The immunogenic composition of claim 1 , wherein said carrier protein is selected from the group comprising inactivated bacterial toxins, bacterial outer membrane proteins, ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), or tuberculin.
3 . The immunogenic composition of claim 1 , wherein said carrier protein is an inactivated bacterial toxin selected of the group comprising tetanus toxoid, diphtheria toxoid, non-toxic cross-reactive material of diphtheria toxin (CRM197), pertussis toxoid, cholera toxoid, E. coli LT, E. coli ST, and exotoxin A from Pseudomona aeruginosa , or any other typical protein carrier used in humans, or any immunogenic peptide/fragments derived from the above.
4 . The immunogenic composition of claim 3 , wherein said carrier protein is tetanus toxoid.
5 . The immunogenic composition of claim 1 , wherein said carrier protein is selected from the group comprising S. suis -derived immunogenic somatic and/or secreted protein selected from, but not restricted to, the group comprising suilysin, MRP, EF, enolase, subtilisin, and DNAse.
6 . The immunogenic composition of claim 1 , wherein said capsular polysaccharide from S. suis is from serotype 2.
7 . The immunogenic composition of claim 1 , wherein said capsular polysaccharide from S. suis is from serotype 1.
8 . The immunogenic composition of claim 1 , wherein said capsular polysaccharide from S. suis is from serotype 7.
9 . The immunogenic composition of claim 1 , wherein said capsular polysaccharide from S. suis is from serotype 9.
10 . The immunogenic composition of claim 5 , wherein said polysaccharides are conjugated to the carrier protein tetanus toxoid.
11 . A multivalent immunogenic composition, comprising: polysaccharide-protein conjugates prepared from at least two different S. suis serotypes, together with a physiologically acceptable vehicle, wherein each conjugate comprises a capsular polysaccharide from Streptococcus suis conjugated to a carrier protein, wherein in said capsular polysaccharides are prepared from Streptococcus suis serotypes 1, 2, 7 and/or 9 or any other serotype.
12 . The multivalent immunogenic composition of claim 10 , wherein said carrier protein is selected from the group comprising inactivated bacterial toxins, bacterial outer membrane proteins, ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), or tuberculin.
13 . The multivalent immunogenic composition of claim 12 , wherein said carrier protein is selected from the group comprising tetanus toxoid, diphtheria toxoid, non-toxic cross-reactive material of diphtheria toxin (CRM197), pertussis toxoid, cholera toxoid, E. coli LT, E. coli ST, and exotoxin A from Pseudomona aeruginosa , or any other typical protein carrier used in humans, or any immunogenic peptide/fragments derived from the above
14 . The immunogenic composition of claim 12 , wherein said carrier protein is selected from the group comprising S. suis -derived immunogenic somatic and/or secreted protein selected from, but not restricted to, the group comprising suilysin, MRP, EF, enolase, subtilisin, and DNAse.
15 . The multivalent immunogenic composition of claim 12 , wherein each capsular polysaccharide is separately conjugated to tetanus toxoid carrier protein.
16 . A method of reducing S. suis associated impaired behavior, lameness, frequency of brain lesions and central nervous system-associated clinical signs, bacteremia, recovery and/or colonization of bacterium from internal tissues, inflammation in thoracic and abdominal cavities, and mortality in swine comprising the administration of the immunogenic composition of claim 1 to an animal in need thereof.
17 . The method of claim 16 , comprising the administration of the immunogenic composition of claim 6 to an animal in need thereof.
18 . The method of claim 16 , comprising the administration of the immunogenic composition of claim 7 to an animal in need thereof.
19 . The method of claim 16 , comprising the administration of the immunogenic composition of claim 8 to an animal in need thereof.
20 . The method of claim 16 , comprising the administration of the immunogenic composition of claim 9 to an animal in need thereof.